Earnings Call · Q2 FY2025·2025-08-05

Q2 25EPS +46.18%·Rev n/aQ1 25EPS +12.40%·Rev n/aQ4 24EPS +34.30%·Rev n/aQ3 24EPS +28.80%·Rev n/a⚠ consensus missing

MADRIGAL PHARMACEUTICALS, INC. MDGL

Tina E. Ventura — Chief Investor Relations Officer

William J. Sibold — Chief Executive Officer

David Soergel — Chief Medical Officer

Mardi C. Dier — Chief Financial Officer

+8.6%1d on move date+9.1% vs SPY3d+9.7%5d+12.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MDGL calls or request research access.

More MDGL calls Browse calls Request research access